about-us/research/open-studies-closed-to-recruitment/
ECLIPSE_M24-305_Poster_V1.0_22SEP2023_UK_EN-3
Abbott - FreeDM2
ADC-UK-PMS-22057_Local-Poster_17Mar23_v1.0_162_Moore-1
CORE Study
A Randomised, Double-blind, Placebo-controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to patients with severe Hypertriglyceridemia. Sponsor: Ionis Pharmaceuticals, Inc.
The purpose of the study is to evaluate the efficacy of Olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
This is a multi-centre, randomized, double-blind, placebo-controlled study in up to approximately 540 participants. Participants will be randomized to receive Olezarsen or placebo in a 53-week treatment period. The length of participation in the study will be approximately 78 weeks, which includes an up to 12-week screening period, a 53-week treatment period, and a 13-week post-treatment evaluation period or transition to open-label extension (OLE) study with up to 1-year treatment.
Recruitment – Closed to recruitment
Lead research staff contact for this study
Sarah Orr
Principal Investigator
Dr Patrick Moore
VENUS
This study is being carried out by to investigate and compare the use of different compression therapy in treating venous leg ulcers.
Venous leg ulcers are common a common problem and can often be recurring, presenting as open wounds on the lower leg. Compression is the first line of treatment for venous leg ulcers. A range of compression therapies such as four-layer bandages, two- layer hosiery, two-layer bandages and compression wraps are regularly used in the NHS.
- 1. Compression wraps (adjustable hook-and-loop-fastened compression): A compression sleeve around the foot and leg
- 2. Four-layer bandage or two-layer compression hosiery: If you are allocated to this treatment group, you and your healthcare professional will decide which treatment you receive. This will be either four layers of compression bandages or two layers of compression stockings
- 3. Two-layer compression bandage: this bandage will comprise of an initial bandage layer with a top compression bandage
We are conducting this study because we are unsure whether one compression therapy is more effective at treating venous leg ulcers than the others. To find the answer to this question, VenUS 6 will recruit and gather important information from a large number of people with a venous leg ulcer(s).
Recruitment – Closed to Recruitment
Lead research staff contact for this study – Wendy Higson & Brenda Furlong
Additional Information
ZEUS
This study is a multinational study by the pharmaceutical company Novo Nordisk, planned recruitment worldwide is 6200, we are looking for about 12 participants. The study drug is called Ziltevekimab, this is an antibody that targets and neutralises inflammation. It is known that inflammation leads to a build-up of fat in the blood vessels. The study is to test if Ziltivekimab can reduce the risk of future cardiovascular events.
The target population is those participants that are high risk of having further cardiovascular events, we are looking for participants with evidence of atherosclerotic cardio vascular disease within the last 5 years. Examples are:
- Myocardial infarction
- Stenosis of major coronary artery
- Stroke of atherosclerotic origin
- Peripheral arterial disease
- Intermittent claudication
- Lower amputation due to atherosclerotic disease
The study can last for up to 4 years.
Recruitment – Closed to recruitment
Lead research staff contact for this study – Sally Bradfield, Tracey Dare & Rebecca Cutts
ATTACK
This study is being carried out by The British heart Foundation and the National Institute for Health Research (NIHR) to test the hypothesis that the addition of 75mg aspirin once daily to usual care reduces the risk of major vascular events in patients with chronic kidney disease (CKD) who do not have pre-existing cardiovascular disease (CVD) .
CKD is common, particularly in older people and ranges from mild, moderate to severe. People who have mild to moderate disease may not even be aware as it doesn’t cause any outward symptoms. However, having CKD is significant because we know that it will increase the risk of developing cardiovascular disease leading to events like heart attacks and strokes later in life.
At present, people who have CKD and who have established cardiovascular disease and have already had a heart attack or stroke, will be prescribed aspirin to help prevent a further episode (this is called “secondary prevention”). However, we don’t yet have evidence to prove that if you have CKD and have not had a heart attack or stroke, that taking aspirin as a preventative measure (this is called “primary prevention”) can offset this risk.
This study will look at whether the taking 75mg aspirin daily (in addition to usual care) reduces risk of major vascular events in people with CKD who do not have pre-existing CVD, and whether and to what extent the benefits outweigh any harms due to increased risk of bleeding.
A positive result from ATTACK will help prevent around 50,000 major vascular events (i.e heart attack or stroke) across the UK over a 5-year period. However, a negative trial result provides definitive evidence to stop aspirin in 1 million people currently taking it for primary prevention of CVD.
Recruitment – 25,000 people will be recruited into this study across the UK. Half of the participants in the trial will be randomised to a daily prescription of Aspirin 75mg daily and half will be randomised to usual care (no aspirin).
Recruitment – CLOSED to recruitment.
Lead research staff contact for this study– Tracey Dare
Principle Investigator for this study – Dr Benjamin Oxley
Additional Information
https://www.southampton.ac.uk/attack-trial/information-for-patients.page
